RXSTNasdaqOphthalmic GoodsFiscal year ends December 31

RxSight, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$4.69+0.18 (+3.99%)

Close on Oct 19, 2026

Market cap: $194.59M
P/E (TTM): –
Dividend yield: –

RxSight, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	134	140	89	49	23	15
Cost of Revenue	31	41	35	28	18	13
Gross Profit	103	99	54	21	4.52	1.71
Research & Development	39	34	29	26	24	22
Selling, General & Admin	113	101	75	59	33	15
Operating Expenses	151	136	104	85	57	37
Operating Income	-48	-37	-50	-63	-53	-35
Interest Expense	0.02	0.02	3.31	4.95	3.68	0.51
Gain (Loss) on Sale of Assets	–	–	–	–	0	0.01
Pretax Income	-39	-27	-49	-67	-49	28
Income Tax Expense	0.07	0.05	0.02	0.01	0.01	0.06
Net Income incl. Noncontrolling Interests	-39	-27	-49	-67	-49	28
Net Income	-39	-27	-49	-67	-49	28
Net Income to Common	–	–	–	–	-49	3.37
EPS (Basic)(per share)	-0.95	-0.71	-1.41	-2.41	-3.57	0.91
EPS (Diluted)(per share)	-0.95	-0.71	-1.41	-2.41	-3.57	0.15
Shares Outstanding (Basic, Weighted)(shares)	41	39	34	28	14	3.71
Shares Outstanding (Diluted, Weighted)(shares)	41	39	34	28	14	5.53
EBITDA	-45	-33	-46	-59	-49	-32

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 77.5%
Operating margin: -43.2%
Net margin: -36.8%
Return on equity, FY2025: -14.0%

Financial strength

Current ratio: 4.07
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 16.6%

Valuation

P/E ratio: –
Price to sales: 1.53
Price to book: 0.74
Dividend yield: –